A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 650 participants.

Also called NCT02551874

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 650 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02551874
  • EudraCT 2015-001702-33
Other papers using this trial's data
  • Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial Diabetes care, 2019-08 DOI, PubMed 31167892

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Denmark, Hungary, Mexico, Poland, Romania, South Africa, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02551874. Randomized; no masking; primary purpose treatment. Start 2015-10-20 (actual); primary completion 2017-05-08 (actual). Results posted on 2018-09-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Saxagliptin, Onglyza
Intervention (Drug)
Dapagliflozin, Farxiga
Intervention (Drug)
Glargine insulin
Intervention (Drug)
Metformin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02551874
Content hash
bbd763f929a8ac29fceebb8eb43f90a0b48a20d314246ca34f9e5007cab5badd